Clinical Trial Update: CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating ribociclib with adjuvant endocrine therapy for ER-positive breast cancer is active but not recruiting at Massachusetts Gener…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KISQALI (ribociclib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING